Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.67 |
| ▸ | EDNRB | P24530 | 14/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | DHPS | P49366 | 1/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.56 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255014 | 0.91 | EDNRA (0.70) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL20000057 | 0.91 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Tezosentan SCHEMBL6963555 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| SCHEMBL6969968 | 0.88 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Tezosentan SCHEMBL29409604 | 0.87 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4524 | 0.87 | EDNRA (0.80) | EDNRAEDNRB | |
| SCHEMBL6962526 | 0.87 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL6959738 | 0.87 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL6962806 | 0.87 | EDNRA (0.62) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Tezosentan SCHEMBL387772 | 0.87 | EDNRA (0.79) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | GULATI ANIL (US) | 2012-03-22 | — | — | US | disclosed |
| US-7973064-B2 | Administering to a mammal therapeutically effective amount of opiate analgesic and endothelin antagonist for therapy and prophylaxis of pain | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010127096-A2 | NOVEL THERAPEUTIC TREATMENTS USING CENTHAQUIN | MIDWESTERN UNIVERSITY (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885ABCC3 1702/4885 |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | EDNRB, EGLN3, BDKRB2 | EDNRA 4/4885EDNRB 1/4885ABCC3 2893/4885 |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | EDNRA 6/4885EDNRB 8/4885ABCC3 2300/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | EDNRA 11/4885EDNRB 8/4885ABCC3 3922/4885 |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885ABCC3 1440/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885ABCC3 1440/4885 |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | EDNRA 6/4885EDNRB 8/4885ABCC3 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.